Compare LQDT & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDT | IOVA |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 985.8M | 1.0B |
| IPO Year | 2005 | 2008 |
| Metric | LQDT | IOVA |
|---|---|---|
| Price | $31.71 | $2.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $40.00 | $10.45 |
| AVG Volume (30 Days) | 147.6K | ★ 9.2M |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.10 | 32.28 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $476,669,000.00 | N/A |
| Revenue This Year | N/A | $60.04 |
| Revenue Next Year | N/A | $58.54 |
| P/E Ratio | $138.46 | ★ N/A |
| Revenue Growth | ★ 31.20 | N/A |
| 52 Week Low | $21.67 | $1.64 |
| 52 Week High | $34.97 | $5.88 |
| Indicator | LQDT | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 57.08 |
| Support Level | $29.67 | $2.47 |
| Resistance Level | $32.02 | $2.68 |
| Average True Range (ATR) | 1.15 | 0.17 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 44.54 | 85.48 |
Liquidity Services Inc is an online auction marketplace. It manages and sells inventory and equipment for business and government clients by operating a network of e-commerce marketplaces that enable buyers and sellers to transact in an efficient, automated environment offering across different product categories. The company has four reportable segments: GovDeals, Retail Supply Chain Group (RSCG), and Machinio & Software Solutions. It generates majority of its revenue from Retail Supply Chain Group (RSCG) segment which consists of marketplaces that enable corporations located in the United States and Canada to sell excess, returned, and overstocked consumer goods. Geographically, a substantial portion the company's revenue is generated from its business in United States.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.